Casadei Gardini Andrea Ricercatore a tempo determinatoMedicinaMED/06
Biografia
Pubblicazioni
Biografia
Ricercatore senior di Oncologia presso Università Vita-Salute San Raffaele, Istituto Scientifico San Raffaele, Milano
POSIZIONI PREGRESSE E TITOLI
- Laurea in Medicina e Chirurgia presso l’Università di Bologna (2008).
- Specializzazione in Oncologia Medica presso l’Università di Ferrara (2014).
- Dirigente medico dal 2014 al 2018 presso il dipartimento di oncologia medica dell’Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS
- Fellowship dal 27/03/2017 fino al 27/12/2017 presso la Clinica Universidad de Navarra, Unita di epatologia, Pamplona, Spagna.
- Da dicembre 2018 a settembre 2020 ricercatore senior presso l’università di Modena e Reggio Emilia.
- Abilitazione scientifica nazionale di seconda fascia settore concorsuale 06/D3- Malattie del sangue, oncologia e reumatologia ottenuta in data 21/01/2020.
ATTIVITA’ ASSISTENZIALI E DI RICERCA
Le attività assistenziali e di ricerca si concentrano principalmente sulla diagnosi e trattamento della patologia oncologica epatobiliare (epatocarcinoma e colangiocarcinoma).
L’attività scientifica si svolge anche attraverso progetti di studi clinici e traslazionali collaborativi internazionali multi-istituzionali – europei e statunitensi.
Autore e coautore di 130 pubblicazioni su riviste internazionali.
Vincitore di diversi bandi italiani e spagnoli su studi clinici e traslazionali sulle patologie epatiche primitive.
Relatore a congressi nazionali ed internazionali.
Revisore scientifico e editor di diverse riviste oncologiche.
Estensore linee guida Associazione Italiana Oncologia Medica sull’epatocarcinoma (2017-presente):
Identificatore univoco del ricercatore:
https://www.scopus.com/authid/detail.uri?authorId=57205570340
https://pubmed.ncbi.nlm.nih.gov/?term=casadei+gardini&sort=date
https://www.linkedin.com/in/andrea-casadei-gardini-229255156/?originalSubdomain=it
Pubblicazioni
1: Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani
S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu
A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini
A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma
patients: Too early or too fast? Crit Rev Oncol Hematol. 2020 Nov 12;157:103167.
doi: 10.1016/j.critrevonc.2020.103167. Epub ahead of print. PMID: 33271389.
2: Pretta A, Ziranu P, Puzzoni M, Lai E, Orsi G, Liscia N, Molinaro E, Mariani
S, Riggi L, Rovesti G, Dubois M, Migliari M, Persano M, Saba G, Impera V, Musio
F, Batzella E, Demurtas L, Pusceddu V, Astara G, Faloppi L, Casadei Gardini A,
Andrikou K, Cascinu S, Scartozzi M. Retrospective survival analysis in patients
with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2
diabetes mellitus. Tumori. 2020 Nov 26:300891620976945. doi:
10.1177/0300891620976945. Epub ahead of print. PMID: 33243068.
3: Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría
E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P,
Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ,
Iraburu MJ, Chen C, Sangro B, Marin JJ, Martinez-Chantar ML, Banales JM, Arnes
R, Huch M, Patino J, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero
FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Dual targeting of
G9a and DNMT1 for the treatment of experimental cholangiocarcinoma. Hepatology.
2020 Nov 22. doi: 10.1002/hep.31642. Epub ahead of print. PMID: 33222246.
4: Molinaro E, Andrikou K, Casadei-Gardini A, Rovesti G. BRCA in
Gastrointestinal Cancers: Current Treatments and Future Perspectives. Cancers
(Basel). 2020 Nov 12;12(11):3346. doi: 10.3390/cancers12113346. PMID: 33198203;
PMCID: PMC7697442.
5: Casadei-Gardini A, Rovesti G, Dadduzio V, Vivaldi C, Lai E, Lonardi S,
Fornaro L, Pretta A, Zagonel V, Bernardini L, Astara G, D'Amico FE, Masi G,
Rimini M, Scartozzi M, Cascinu S. Impact of Aspirin on clinical outcome in
advanced HCC patients receiving sorafenib and regorafenib. HPB (Oxford). 2020
Nov 12:S1365-182X(20)31183-7. doi: 10.1016/j.hpb.2020.09.024. Epub ahead of
print. PMID: 33191108.
6: Pelizzaro F, Penzo B, Peserico G, Imondi A, Sartori A, Vitale A, Cillo U,
Giannini EG, Forgione A, Ludovico Rapaccini G, Di Marco M, Caturelli E, Zoli M,
Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni
G, Giuseppe Foschi F, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F,
Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA)
group. Monofocal hepatocellular carcinoma: How much does size matter? Liver Int.
2020 Nov 6. doi: 10.1111/liv.14718. Epub ahead of print. PMID: 33155401.
7: Rimini M, Rovesti G, Casadei-Gardini A. Child Pugh and ALBI grade: past,
present or future? Ann Transl Med. 2020 Sep;8(17):1044. doi:
10.21037/atm-20-3709. PMID: 33145263; PMCID: PMC7575984.
8: Mazzoni F, Petreni P, Vasile E, Panebianco M, Casadei-Gardini A, Negri F,
Lunghi A, Pillozzi S, Vivaldi C, Gervasi E, Frassineti GL, Messerini L, Jocollé
G, Bisagni A, Antonuzzo L, Rossi G. <i>ROS1</i> rearrangements are uncommon in
biliary tract cancers. Oncol Lett. 2020 Dec;20(6):316. doi:
10.3892/ol.2020.12179. Epub 2020 Oct 1. PMID: 33133252; PMCID: PMC7590438.
9: Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F,
Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi
S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F,
Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Correction
to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated
Hepatocellular Carcinoma. Target Oncol. 2020 Dec;15(6):809-810. doi:
10.1007/s11523-020-00765-3. Erratum for: Target Oncol. 2020 Dec;15(6):773-785.
PMID: 33113041.
10: Casadei Gardini A, Scarpi E, Valgiusti M, Monti M, Ruscelli S, Matteucci L,
Bartolini G, Vertogen B, Pagan F, Rovesti G, Frassineti GL, Passardi A.
Prognostic role of a new index (multi inflammatory index) in patients with
metastatic colorectal cancer: results from the randomized ITACa trial. Ther Adv
Med Oncol. 2020 Sep 28;12:1758835920958363. doi: 10.1177/1758835920958363. PMID:
33062063; PMCID: PMC7534088.
11: Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F,
Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi
S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F,
Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Prognostic
Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular
Carcinoma. Target Oncol. 2020 Dec;15(6):773-785. doi:
10.1007/s11523-020-00757-3. Erratum in: Target Oncol. 2020 Oct 28;: PMID:
33044683.
12: Canale M, Casadei-Gardini A, Ulivi P, Arechederra M, Berasain C, Lollini PL,
Fernández-Barrena MG, Avila MA. Epigenetic Mechanisms in Gastric Cancer:
Potential New Therapeutic Opportunities. Int J Mol Sci. 2020 Jul 31;21(15):5500.
doi: 10.3390/ijms21155500. PMID: 32752096; PMCID: PMC7432799.
13: Vivaldi C, Salani F, Rovesti G, Pecora I, Catanese S, Casadei-Gardini A,
Massa V, Bernardini L, Riggi L, Andrikou K, Rapposelli GI, Formica V, Lencioni
M, Falcone A, Vasile E, Fornaro L. First-line gemcitabine plus nab-paclitaxel
for elderly patients with metastatic pancreatic cancer: Crossing the frontier of
age? Eur J Cancer. 2020 Sep;137:108-116. doi: 10.1016/j.ejca.2020.06.031. Epub
2020 Aug 1. PMID: 32750500.
14: Roviello G, Casadei-Gardini A, Nobili S, Mini E, Fancelli S. Defining the
Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. J Oncol.
2020 Jun 19;2020:8024124. doi: 10.1155/2020/8024124. PMID: 32655640; PMCID:
PMC7321521.
15: Gelsomino F, Spallanzani A, Casadei-Gardini A. Comment on Chun et al, "A
Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus
Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable
Hepatic Colorectal Metastases". Clin Colorectal Cancer. 2020
Dec;19(4):e262-e263. doi: 10.1016/j.clcc.2020.06.002. Epub 2020 Jun 10. PMID:
32646655.
16: Vega-Benedetti AF, Loi E, Moi L, Orrù S, Ziranu P, Pretta A, Lai E, Puzzoni
M, Ciccone L, Casadei-Gardini A, Cabras F, Fortunato F, Restivo A, Zorcolo L,
Scartozzi M, Zavattari P. Colorectal Cancer Early Detection in Stool Samples
Tracing CpG Islands Methylation Alterations Affecting Gene Expression. Int J Mol
Sci. 2020 Jun 24;21(12):4494. doi: 10.3390/ijms21124494. PMID: 32599859; PMCID:
PMC7349989.
17: Neuzillet C, Casadei-Gardini A, Brieau B, Vivaldi C, Brandi G, Tougeron D,
Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau B, Scartozzi
M, Dahan L, Aprile G, Le Sourd S, Evesque L, Meurisse A, Lièvre A, Vernerey D;
AGEO (Association des Gastro-Entérologues Oncologues) Investigators; GICO
(Italian Group of Cholangiocarcinoma) Investigators. Fluropyrimidine single
agent or doublet chemotherapy as second line treatment in advanced biliary tract
cancer. Int J Cancer. 2020 Dec 1;147(11):3177-3188. doi: 10.1002/ijc.33146. Epub
2020 Jul 7. PMID: 32525595.
18: Casadei-Gardini A, Dadduzio V, Rovesti G, Cabibbo G, Vukotic R, Rizzato MD,
Orsi G, Rossi M, Guarneri V, Lonardi S, D'agostino D, Celsa C, Andreone P,
Zagonel V, Scartozzi M, Cascinu S, Cucchetti A. Utility of neutrophil-to-
lymphocyte ratio to identify long-term survivors among HCC patients treated with
sorafenib. Medicine (Baltimore). 2020 May 29;99(22):e19958. doi:
10.1097/MD.0000000000019958. PMID: 32481366.
19: Marconato L, Sabattini S, Marisi G, Rossi F, Leone VF, Casadei-Gardini A.
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma:
Preliminary Toxicity and Activity Data in Dogs. Cancers (Basel). 2020 May
18;12(5):1272. doi: 10.3390/cancers12051272. PMID: 32443457; PMCID: PMC7281367.
20: Gelsomino F, Casadei-Gardini A, Caputo F, Rossi G, Bertolini F, Petrachi T,
Spallanzani A, Pettorelli E, Kaleci S, Luppi G. mTOR Pathway Expression as
Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors
Treated with Everolimus. Cancers (Basel). 2020 May 10;12(5):1201. doi:
10.3390/cancers12051201. PMID: 32397669; PMCID: PMC7281483.
21: D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib
as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin
Pharmacol. 2020 Jun;13(6):623-629. doi: 10.1080/17512433.2020.1767591. Epub 2020
May 22. PMID: 32394749.
22: Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C,
Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F,
Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G,
Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to
predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
PLoS One. 2020 May 7;15(5):e0232449. doi: 10.1371/journal.pone.0232449. PMID:
32379785; PMCID: PMC7205300.
23: Casadei-Gardini A, Marisi G, Dadduzio V, Gramantieri L, Faloppi L, Ulivi P,
Foschi FG, Tamburini E, Vivaldi C, Rizzato MD, Ielasi L, Canale M, Conti F,
Rudnas B, Fornaro L, Silvestris N, Silletta M, Cardellino GG, Lonardi S, Fornari
F, Orsi G, Rovesti G, Zagonel V, Cascinu S, Scartozzi M. Association of
<i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with
Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter
Prospective INNOVATE Study. Clin Cancer Res. 2020 Sep 1;26(17):4485-4493. doi:
10.1158/1078-0432.CCR-19-3897. Epub 2020 May 5. PMID: 32371540.
24: Gelsomino F, Casadei-Gardini A, Rossini D, Boccaccino A, Masi G, Cremolini
C, Spallanzani A, Viola MG, Garajovà I, Salati M, Elia MT, Caputo F, Santini C,
Falcone A, Cascinu S, Tamburini E. The Role of Anti-Angiogenics in Pre-Treated
Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis. Cancers
(Basel). 2020 Apr 21;12(4):1022. doi: 10.3390/cancers12041022. PMID: 32326305;
PMCID: PMC7226019.
25: Rimini M, Casadei-Gardini A, Ravaioli A, Rovesti G, Conti F, Borghi A,
Dall'Aglio AC, Bedogni G, Domenicali M, Giacomoni P, Tiribelli C, Bucchi L,
Falcini F, Foschi FG, Bagnacavallo Study Group. Could Inflammatory Indices and
Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the
Bagnacavallo Population Study. J Clin Med. 2020 Apr 20;9(4):1177. doi:
10.3390/jcm9041177. PMID: 32325965; PMCID: PMC7231063.
26: Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi
G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Is There an
Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. Clin
Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001.
Epub 2020 Mar 17. PMID: 32192883.
27: de la Torre-Aláez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI,
Rodriguez-Fraile M, Sancho L, D'Avola D, Herrero JI, Iñarrairaegui M, Sangro B.
The Pattern of Progression Defines Post-progression Survival in Patients with
Hepatocellular Carcinoma Treated with SIRT. Cardiovasc Intervent Radiol. 2020
Aug;43(8):1165-1172. doi: 10.1007/s00270-020-02444-2. Epub 2020 Mar 12. PMID:
32166352.
28: Cucchetti A, Evans D, Casadei-Gardini A, Piscaglia F, Maroni L, Odaldi F,
Ercolani G. The Perceived Ability of Gastroenterologists, Hepatologists and
Surgeons Can Bias Medical Decision Making. Int J Environ Res Public Health. 2020
Feb 7;17(3):1058. doi: 10.3390/ijerph17031058. PMID: 32046089; PMCID:
PMC7037552.
29: Faloppi L, Puzzoni M, Casadei Gardini A, Silvestris N, Masi G, Marisi G,
Vivaldi C, Gadaleta CD, Ziranu P, Bianconi M, Loretelli C, Demurtas L, Lai E,
Giampieri R, Galizia E, Ulivi P, Battelli N, Falcone A, Cascinu S, Scartozzi M.
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced
Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Target Oncol.
2020 Feb;15(1):115-126. doi: 10.1007/s11523-020-00698-x. Erratum in: Target
Oncol. 2020 Dec;15(6):801-802. PMID: 32020517.
30: Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M,
Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri
F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F.
MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i>/<i>TP53</i> Axis and
Predicts Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Res. 2020 Apr
15;80(8):1720-1734. doi: 10.1158/0008-5472.CAN-19-0472. Epub 2020 Feb 3. PMID:
32015093.
31: Casadei-Gardini A, Del Coco L, Marisi G, Conti F, Rovesti G, Ulivi P, Canale
M, Frassineti GL, Foschi FG, Longo S, Fanizzi FP, Giudetti AM. <sup>1</sup>H-NMR
Based Serum Metabolomics Highlights Different Specific Biomarkers between Early
and Advanced Hepatocellular Carcinoma Stages. Cancers (Basel). 2020 Jan
18;12(1):241. doi: 10.3390/cancers12010241. PMID: 31963766; PMCID: PMC7016798.
32: Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A,
Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL,
Romeo A. Erratum: Passardi, A. et al<i>.</i> Chemoradiotherapy (Gemox Plus
Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A
Phase II Study. <i>Cancers</i> 2019, <i>11</i>, 663. Cancers (Basel). 2020 Jan
10;12(1):178. doi: 10.3390/cancers12010178. Erratum for: Cancers (Basel). 2019
May 13;11(5): PMID: 31936817; PMCID: PMC7016811.
33: Casadei-Gardini A, Orsi G, Caputo F, Ercolani G. Developments in predictive
biomarkers for hepatocellular carcinoma therapy. Expert Rev Anticancer Ther.
2020 Jan;20(1):63-74. doi: 10.1080/14737140.2020.1712198. Epub 2020 Jan 7. PMID:
31910040.
34: Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K,
Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P,
Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N,
Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic
nutritional index predicts survival and response to first-line chemotherapy in
advanced biliary cancer. Liver Int. 2020 Mar;40(3):704-711. doi:
10.1111/liv.14314. Epub 2019 Dec 11. PMID: 31773848.
35: Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG,
Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M,
Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P,
Scartozzi M, Cascinu S, Casadei-Gardini A. Impact of Baseline Characteristics on
the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of
Experience. Gastrointest Tumors. 2019 Oct;6(3-4):92-107. doi: 10.1159/000502714.
Epub 2019 Sep 12. PMID: 31768353; PMCID: PMC6873043.
36: Casadei-Gardini A, Solaini L, Riggi L, Molinaro E, Dadduzio V, Rizzato MD,
Pellino A, Faloppi L, Marisi G, Ulivi P, Canale M, Orsi G, Rovesti G, Andrikou
K, Spallanzani A, Gelsomino F, Foschi FG, Conti F, Cucchetti A, Ercolani G,
Biason P, Lonardi S, Cascinu S, Scartozzi M. Prognostic Role of a New Index
(RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib:
Training and Validation Cohort. Gastrointest Tumors. 2019 Oct;6(3-4):71-80. doi:
10.1159/000501593. Epub 2019 Aug 20. PMID: 31768351; PMCID: PMC6873000.
37: Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A,
Andrikou K, Cascinu S, Gelsomino F. BRAF-Mutated Colorectal Cancer: Clinical and
Molecular Insights. Int J Mol Sci. 2019 Oct 28;20(21):5369. doi:
10.3390/ijms20215369. PMID: 31661924; PMCID: PMC6861966.
38: Brunetti O, Gnoni A, Licchetta A, Longo V, Calabrese A, Argentiero A,
Delcuratolo S, Solimando AG, Casadei-Gardini A, Silvestris N. Predictive and
Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Kaunas).
2019 Oct 21;55(10):707. doi: 10.3390/medicina55100707. PMID: 31640191; PMCID:
PMC6843290.
39: Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro
F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per
lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and
Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers (Basel). 2019
Oct 15;11(10):1568. doi: 10.3390/cancers11101568. PMID: 31618961; PMCID:
PMC6826649.
40: Cabibbo G, Cucchetti A, Cammà C, Casadei-Gardini A, Celsa C, Emanuele Maria
Rizzo G, Johnson P, Ercolani G. Outcomes of hepatocellular carcinoma patients
treated with sorafenib: a meta-analysis of Phase III trials. Future Oncol. 2019
Oct;15(29):3411-3422. doi: 10.2217/fon-2019-0287. Epub 2019 Oct 7. PMID:
31588789.
41: Fornaro L, Leone F, Vienot A, Casadei-Gardini A, Vivaldi C, Lièvre A,
Lombardi P, De Luca E, Vernerey D, Sperti E, Musettini G, Satolli MA, Edeline J,
Spadi R, Neuzillet C, Falcone A, Pasquini G, Clerico M, Passardi A, Buscaglia P,
Meurisse A, Aglietta M, Brac C, Vasile E, Montagnani F. Validated Nomogram
Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line
5-Fluorouracil, Oxaliplatin, and Irinotecan. Clin Colorectal Cancer. 2019
Dec;18(4):e394-e401. doi: 10.1016/j.clcc.2019.08.004. Epub 2019 Sep 4. PMID:
31564556.
42: Orsi G, Casadei-Gardini A. Sorafenib and metformin: to be, or not to be,
that is the question. Hepatobiliary Surg Nutr. 2019 Aug;8(4):411-413. doi:
10.21037/hbsn.2019.04.01. PMID: 31489317; PMCID: PMC6700026.
43: Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G,
Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with
tailored sorafenib dosing prolongs survival of hepatocellular carcinoma
patients. J Hepatol. 2019 Dec;71(6):1175-1183. doi: 10.1016/j.jhep.2019.08.015.
Epub 2019 Aug 23. PMID: 31449860.
44: Casadei-Gardini A, Montagnani F, Casadei C. Immune inflammation indicators
in anal cancer patients treated with concurrent chemoradiation: training and
validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
[Corrigendum]. Cancer Manag Res. 2019 Jun 25;11:5123. doi: 10.2147/CMAR.S215110.
Erratum for: Cancer Manag Res. 2019 Apr 26;11:3631-3642. PMID: 31417303; PMCID:
PMC6599855.
45: Marisi G, Petracci E, Raimondi F, Faloppi L, Foschi FG, Lauletta G, Iavarone
M, Canale M, Valgiusti M, Neri LM, Ulivi P, Orsi G, Rovesti G, Vukotic R, Conti
F, Cucchetti A, Ercolani G, Andrikou K, Cascinu S, Scartozzi M, Casadei-Gardini
A. <i>ANGPT2</i> and <i>NOS3</i> Polymorphisms and Clinical Outcome in Advanced
Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers (Basel). 2019 Jul
20;11(7):1023. doi: 10.3390/cancers11071023. PMID: 31330833; PMCID: PMC6679015.
46: Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, Arcella A,
Badiali M, Giangaspero F, Morra I, Columbano A, Restivo A, Zorcolo L, Gismondi
V, Varesco L, Bellomo SE, Giordano S, Canale M, Casadei-Gardini A, Faloppi L,
Puzzoni M, Scartozzi M, Ziranu P, Cabras G, Cocco P, Ennas MG, Satta G, Zucca M,
Canzio D, Zavattari P. Clustered protocadherins methylation alterations in
cancer. Clin Epigenetics. 2019 Jul 9;11(1):100. doi: 10.1186/s13148-019-0695-0.
PMID: 31288858; PMCID: PMC6617643.
47: Vergara D, Casadei-Gardini A, Giudetti AM. Oxidative Molecular Mechanisms
Underlying Liver Diseases: From Systems Biology to the Personalized Medicine.
Oxid Med Cell Longev. 2019 Jun 2;2019:7864316. doi: 10.1155/2019/7864316. PMID:
31281591; PMCID: PMC6589262.
48: Tovoli F, Casadei-Gardini A, Benevento F, Piscaglia F. Immunotherapy for
hepatocellular carcinoma: A review of potential new drugs based on ongoing
clinical studies as of 2019. Dig Liver Dis. 2019 Aug;51(8):1067-1073. doi:
10.1016/j.dld.2019.05.006. Epub 2019 Jun 14. PMID: 31208929.
49: Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini
I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M,
Frassineti GL, Passardi A. Prognostic role of a new inflammatory index with
neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon
Inflammatory Index) in patients with metastatic colorectal cancer: results from
the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. Cancer
Manag Res. 2019 May 10;11:4357-4369. doi: 10.2147/CMAR.S198651. Erratum in:
Cancer Manag Res. 2020 Jan 23;12:541. PMID: 31191000; PMCID: PMC6522652.
50: Solaini L, Gardini A, Passardi A, Mirarchi MT, D'Acapito F, La Barba G,
Cucchi M, Casadei Gardini A, Frassineti GL, Cucchetti A, Ercolani G.
Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver
Metastasis Patients: A Propensity Score-Matched Analysis. Am Surg. 2019 May
1;85(5):488-493. PMID: 31126361.
51: Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi
D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC,
Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell'Acqua V,
Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P.
Immune inflammation indicators in anal cancer patients treated with concurrent
chemoradiation: training and validation cohort with online calculator (ARC: Anal
Cancer Response Classifier). Cancer Manag Res. 2019 Apr 26;11:3631-3642. doi:
10.2147/CMAR.S197349. Erratum in: Cancer Manag Res. 2019 Jun 25;11:5123. PMID:
31118786; PMCID: PMC6506779.
52: Casadei Gardini A, Puzzoni M, Montagnani F, Marisi G, Tamburini E, Cucchetti
A, Solaini L, Foschi FG, Conti F, Ercolani G, Cascinu S, Scartozzi M. Profile of
lenvatinib in the treatment of hepatocellular carcinoma: design, development,
potential place in therapy and network meta-analysis of hepatitis B and
hepatitis C in all Phase III trials. Onco Targets Ther. 2019 Apr
24;12:2981-2988. doi: 10.2147/OTT.S192572. PMID: 31118665; PMCID: PMC6499482.
53: Del Coco L, Vergara D, De Matteis S, Mensà E, Sabbatinelli J, Prattichizzo
F, Bonfigli AR, Storci G, Bravaccini S, Pirini F, Ragusa A, Casadei-Gardini A,
Bonafè M, Maffia M, Fanizzi FP, Olivieri F, Giudetti AM. NMR-Based Metabolomic
Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients
with Type 2 Diabetes Mellitus. J Clin Med. 2019 May 21;8(5):720. doi:
10.3390/jcm8050720. PMID: 31117294; PMCID: PMC6571571.
54: Passardi A, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Gardini A, La
Barba G, Pagan F, Casadei-Gardini A, Valgiusti M, Ferroni F, Frassineti GL,
Romeo A. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable
Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers (Basel). 2019 May
13;11(5):663. doi: 10.3390/cancers11050663. Erratum in: Cancers (Basel). 2020
Jan 10;12(1): PMID: 31086093; PMCID: PMC6562444.
55: Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G,
Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De
Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Santini D,
Doglioni C, Maiello E, Lawlor RT, Mazzaferro V, Lonardi S, Giuliante F, Brandi
G, Scarpa A, Cascinu S, Silvestris N. The Italian Rare Pancreatic Exocrine
Cancer Initiative. Tumori. 2019 Aug;105(4):353-358. doi:
10.1177/0300891619839461. Epub 2019 Apr 9. Erratum in: Tumori. 2020 Mar
16;:300891620914460. PMID: 30967031.
56: Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y,
Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath
I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS,
Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Doxorubicin-
loaded nanoparticles for patients with advanced hepatocellular carcinoma after
sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi:
10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Erratum in: Lancet Gastroenterol
Hepatol. 2019 Jul;4(7):e6. Erratum in: Lancet Gastroenterol Hepatol. 2020
Feb;5(2):e1. PMID: 30954567.
57: Solaini L, D'Acapito F, Passardi A, Framarini M, Tauceri F, Di Pietrantonio
D, Frassineti GL, Casadei Gardini A, Cucchetti A, Cavaliere D, Ercolani G.
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal
carcinomatosis in colorectal cancer patients: a single-center cohort study.
World J Surg Oncol. 2019 Mar 27;17(1):58. doi: 10.1186/s12957-019-1602-z. PMID:
30917826; PMCID: PMC6437853.
58: De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G,
Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A,
Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S,
Casadei-Gardini A. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma
Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with
Metformin. Int J Mol Sci. 2019 Mar 26;20(6):1503. doi: 10.3390/ijms20061503.
PMID: 30917505; PMCID: PMC6470641.
59: Cucchetti A, Casadei Gardini A. Incorporating alpha-fetoprotein within
dimensional criteria for hepatocellular carcinoma transplantation. Hepatobiliary
Surg Nutr. 2019 Feb;8(1):65-66. doi: 10.21037/hbsn.2018.11.02. PMID: 30881969;
PMCID: PMC6383020.
60: Neuzillet C, Casadei Gardini A, Brieau B, Vivaldi C, Smolenschi C, Brandi G,
Tougeron D, Filippi R, Vienot A, Silvestris N, Pointet AL, Lonardi S, Rousseau
B, Scartozzi M, Dahan L, Aprile G, Boussaha T, Malka D, Crusz SM, Le Sourd S,
Meurisse A, Lièvre A, Vernerey D; AGEO (Association des Gastro-Entérologues
Oncologues); GICO (Italian Group of Cholangiocarcinoma) Investigators; Gustave
Roussy Institute Cohort; Barts Cancer Institute Cohort. Prediction of survival
with second-line therapy in biliary tract cancer: Actualisation of the AGEO
CT2BIL cohort and European multicentre validations. Eur J Cancer. 2019
Apr;111:94-106. doi: 10.1016/j.ejca.2019.01.019. Epub 2019 Mar 1. PMID:
30826661.
61: De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafè
M, Giudetti AM. Aberrant Metabolism in Hepatocellular Carcinoma Provides
Diagnostic and Therapeutic Opportunities. Oxid Med Cell Longev. 2018 Nov
4;2018:7512159. doi: 10.1155/2018/7512159. PMID: 30524660; PMCID: PMC6247426.
62: Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei
Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. IL-8 and thrombospondin-1
as prognostic markers in patients with metastatic colorectal cancer receiving
bevacizumab. Cancer Manag Res. 2018 Nov 14;10:5659-5666. doi:
10.2147/CMAR.S181570. PMID: 30532588; PMCID: PMC6241685.
63: Casadei Gardini A, Scarpi E, Foschi FG, Marisi G, Maltoni M, Frassineti GL.
Impact of physician experience and multidisciplinary team on clinical outcome in
patients receiving sorafenib. Clin Res Hepatol Gastroenterol. 2019
Oct;43(5):e76-e78. doi: 10.1016/j.clinre.2018.11.005. Epub 2018 Dec 5. PMID:
30528062.
64: Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B.
Radioembolization versus chemoembolization for unresectable hepatocellular
carcinoma: a meta-analysis of randomized trials. Onco Targets Ther. 2018 Oct
25;11:7315-7321. doi: 10.2147/OTT.S175715. PMID: 30498358; PMCID: PMC6207245.
65: Foschi FG, Bedogni G, Domenicali M, Giacomoni P, Dall'Aglio AC, Dazzani F,
Lanzi A, Conti F, Savini S, Saini G, Bernardi M, Andreone P, Gastaldelli A,
Casadei Gardini A, Tiribelli C, Bellentani S, Stefanini GF. Prevalence of and
risk factors for fatty liver in the general population of Northern Italy: the
Bagnacavallo Study. BMC Gastroenterol. 2018 Nov 28;18(1):177. doi:
10.1186/s12876-018-0906-8. PMID: 30486798; PMCID: PMC6262973.
66: Scarpi E, Dall'Agata M, Zagonel V, Gamucci T, Bertè R, Sansoni E, Amaducci
E, Broglia CM, Alquati S, Garetto F, Schiavon S, Quadrini S, Orlandi E, Casadei
Gardini A, Ruscelli S, Ferrari D, Pino MS, Bortolussi R, Negri F, Stragliotto S,
Narducci F, Valgiusti M, Farolfi A, Nanni O, Rossi R, Maltoni M; Early
Palliative Care Italian Study Group (EPCISG). Systematic vs. on-demand early
palliative care in gastric cancer patients: a randomized clinical trial
assessing patient and healthcare service outcomes. Support Care Cancer. 2019
Jul;27(7):2425-2434. doi: 10.1007/s00520-018-4517-2. Epub 2018 Oct 24. PMID:
30357555.
67: Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, Marisi G,
Buonfiglioli F, Vitale G, Ravaioli F, Gitto S, Verucchi G, Lenzi M, Bolondi L,
Mazzella G, Brillanti S, Andreone P; member of the Bologna DAA group. Immune
inflammation indicators and ALBI score to predict liver cancer in HCV-patients
treated with direct-acting antivirals. Dig Liver Dis. 2019 May;51(5):681-688.
doi: 10.1016/j.dld.2018.09.016. Epub 2018 Sep 22. PMID: 30327251.
68: Casadei Gardini A, Marisi G, Canale M, Foschi FG, Donati G, Ercolani G,
Valgiusti M, Passardi A, Frassineti GL, Scarpi E. Radiofrequency ablation of
hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-
free survival. Onco Targets Ther. 2018 Oct 5;11:6555-6567. doi:
10.2147/OTT.S170836. PMID: 30323628; PMCID: PMC6178942.
69: Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG,
De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei
Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any
predictive and/or prognostic markers? World J Gastroenterol. 2018 Sep
28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152. PMID: 30271080; PMCID:
PMC6158485.
70: Casadei Gardini A, Scarpi E, Orlandi E, Tassinari D, Leo S, Bernardini I,
Gelsomino F, Tamberi S, Ruscelli S, Vespignani R, Ronconi S, Frassineti GL,
Amadori D, Passardi A. Prognostic role of aspartate aminotransferase-lymphocyte
ratio index in patients with metastatic colorectal cancer: results from the
randomized ITACa trial. Onco Targets Ther. 2018 Aug 29;11:5261-5268. doi:
10.2147/OTT.S166614. PMID: 30214231; PMCID: PMC6120511.
71: Franco P, De Bari B, Arcadipane F, Lepinoy A, Ceccarelli M, Furfaro G,
Mistrangelo M, Cassoni P, Valgiusti M, Passardi A, Casadei Gardini A, Trino E,
Martini S, Iorio GC, Evangelista A, Ricardi U, Créhange G. Comparing
simultaneous integrated boost vs sequential boost in anal cancer patients:
results of a retrospective observational study. Radiat Oncol. 2018 Sep
10;13(1):172. doi: 10.1186/s13014-018-1124-9. PMID: 30201015; PMCID: PMC6131808.
72: Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Special
Interest Group on Hepatocellular carcinoma and new anti-HCV therapies” of the
Italian Association for the Study of the Liver. Recurrence of hepatocellular
carcinoma after direct acting antiviral treatment for hepatitis C virus
infection: Literature review and risk analysis. Dig Liver Dis. 2018
Nov;50(11):1105-1114. doi: 10.1016/j.dld.2018.08.001. Epub 2018 Aug 11. PMID:
30170908.
73: Canale M, Ulivi P, Foschi FG, Scarpi E, De Matteis S, Donati G, Ercolani G,
Scartozzi M, Faloppi L, Passardi A, Tamburini E, Valgiusti M, Marisi G,
Frassineti GL, Casadei Gardini A. Clinical and circulating biomarkers of
survival and recurrence after radiofrequency ablation in patients with
hepatocellular carcinoma. Crit Rev Oncol Hematol. 2018 Sep;129:44-53. doi:
10.1016/j.critrevonc.2018.06.017. Epub 2018 Jun 23. PMID: 30097237.
74: Mori G, Rampelli S, Orena BS, Rengucci C, De Maio G, Barbieri G, Passardi A,
Casadei Gardini A, Frassineti GL, Gaiarsa S, Albertini AM, Ranzani GN, Calistri
D, Pasca MR. Shifts of Faecal Microbiota During Sporadic Colorectal
Carcinogenesis. Sci Rep. 2018 Jul 9;8(1):10329. doi: 10.1038/s41598-018-28671-9.
PMID: 29985435; PMCID: PMC6037773.
75: Massa I, Nanni O, Foca F, Maltoni M, Derni S, Gentili N, Frassineti GL,
Casadei Gardini A, Valgiusti M, Amadori D, Prati E, Altini M, Gallegati D,
Sansoni E. Chemotherapy and palliative care near end-of life: examining the
appropriateness at a cancer institute for colorectal cancer patients. BMC
Palliat Care. 2018 Jun 19;17(1):86. doi: 10.1186/s12904-018-0339-8. PMID:
29914452; PMCID: PMC6006864.
76: Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M,
Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R,
Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D,
Reni M, Cascinu S, Silvestris N. Systemic Chemotherapy for Advanced Rare
Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis. Pancreas.
2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063. PMID: 29771769.
77: Casadei Gardini A, Conti F, Foschi FG, Brillanti S, Andreone P; members of
Bologna DAA group. Imbalance of Neutrophils and Lymphocyte Counts Can Be
Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related
Cirrhosis Treated With Direct-acting Antivirals. Gastroenterology. 2018
Jun;154(8):2281-2282. doi: 10.1053/j.gastro.2017.12.051. Epub 2018 May 7. PMID:
29746809.
78: Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG,
Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F,
Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G,
Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F;
Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across
hepatocellular carcinoma in Italy. Liver Int. 2018 Nov;38(11):2028-2039. doi:
10.1111/liv.13877. Epub 2018 Jun 19. PMID: 29745475.
79: Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Martini S,
Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Cascinu S, Ricardi
U, Casadei Gardini A. The prognostic role of hemoglobin levels in patients
undergoing concurrent chemo-radiation for anal cancer. Radiat Oncol. 2018 May
2;13(1):83. doi: 10.1186/s13014-018-1035-9. PMID: 29720197; PMCID: PMC5930791.
80: Casadei Gardini A, Passardi A, Fornaro L, Rosetti P, Valgiusti M, Ruscelli
S, Monti M, Casadei C, Pagan F, Frassineti GL. Treatment of squamous cell
carcinoma of the anal canal: A new strategies with anti-EGFR therapy and
immunotherapy. Crit Rev Oncol Hematol. 2018 Mar;123:52-56. doi:
10.1016/j.critrevonc.2018.01.007. Epub 2018 Feb 2. PMID: 29482779.
81: Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A,
Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A.
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of
bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol.
2018 Jul;28(7):2969-2978. doi: 10.1007/s00330-017-5254-5. Epub 2018 Feb 7. PMID:
29417252.
82: Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A,
Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F,
Sacco R, Di Costanzo GG. Metronomic capecitabine as second-line treatment for
hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin
Oncol. 2018 Feb;144(2):403-414. doi: 10.1007/s00432-017-2556-6. Epub 2017 Dec
16. PMID: 29249005.
83: Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG,
Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti
O, Cardellino GG, Frassineti GL, Scartozzi M. Antiangiogenic agents after first
line and sorafenib plus chemoembolization: a systematic review. Oncotarget. 2017
Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. PMID: 29029548; PMCID:
PMC5630448.
84: Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli
F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G,
Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi
A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Metformin and insulin
impact on clinical outcome in patients with advanced hepatocellular carcinoma
receiving sorafenib: Validation study and biological rationale. Eur J Cancer.
2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3. PMID:
28985579.
85: Casadei Gardini A, Valgiusti M, Passardi A, Frassineti GL. Treatment of
squamous cell carcinoma of the anal canal (SCCA): a new era? Ann Oncol. 2017 Oct
1;28(10):2620. doi: 10.1093/annonc/mdx291. PMID: 28945890.
86: Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D,
Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M,
Ulivi P, Amadori D. Impact of second-line cetuximab-containing therapy in
patients with KRAS wild-type metastatic colorectal cancer: results from the
ITACa randomized clinical trial. Sci Rep. 2017 Sep 5;7(1):10426. doi:
10.1038/s41598-017-11048-9. PMID: 28874797; PMCID: PMC5585399.
87: Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata
R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G,
Tortora R. Validation of a Simple Scoring System to Predict Sorafenib
Effectiveness in Patients with Hepatocellular Carcinoma. Target Oncol. 2017
Dec;12(6):795-803. doi: 10.1007/s11523-017-0522-5. PMID: 28770532.
88: Ulivi P, Scarpi E, Chiadini E, Marisi G, Valgiusti M, Capelli L, Casadei
Gardini A, Monti M, Ruscelli S, Frassineti GL, Calistri D, Amadori D, Passardi
A. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor
Biology and Bevacizumab Efficacy. Int J Mol Sci. 2017 Jun 9;18(6):1240. doi:
10.3390/ijms18061240. PMID: 28598398; PMCID: PMC5486063.
89: Passardi A, Fanini F, Turci L, Foca F, Rosetti P, Ruscelli S, Casadei
Gardini A, Valgiusti M, Dazzi C, Marangolo M. Prolonged Pemetrexed Infusion Plus
Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale
and Phase II Study Results. Oncologist. 2017 Aug;22(8):886-e79. doi:
10.1634/theoncologist.2017-0206. Epub 2017 Jun 7. PMID: 28592624; PMCID:
PMC5553965.
90: Casadei Gardini A, Frassineti GL, Foschi FG, Ercolani G, Ulivi P. Sorafenib
and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients:
Analysis of RESORCE and SHARP trials. Dig Liver Dis. 2017 Aug;49(8):943-944.
doi: 10.1016/j.dld.2017.04.022. Epub 2017 May 6. PMID: 28546063.
91: De Matteis S, Granato AM, Napolitano R, Molinari C, Valgiusti M, Santini D,
Foschi FG, Ercolani G, Vespasiani Gentilucci U, Faloppi L, Scartozzi M,
Frassineti GL, Casadei Gardini A. Interplay Between SIRT-3, Metabolism and Its
Tumor Suppressor Role in Hepatocellular Carcinoma. Dig Dis Sci. 2017
Aug;62(8):1872-1880. doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19. PMID:
28527050.
92: Ongaro E, Buoro V, Cinausero M, Caccialanza R, Turri A, Fanotto V, Basile D,
Vitale MG, Ermacora P, Cardellino GG, Nicoletti L, Fornaro L, Casadei-Gardini A,
Aprile G. Sarcopenia in gastric cancer: when the loss costs too much. Gastric
Cancer. 2017 Jul;20(4):563-572. doi: 10.1007/s10120-017-0722-9. Epub 2017 May 5.
PMID: 28477106.
93: Marisi G, Scarpi E, Passardi A, Nanni O, Ragazzini A, Valgiusti M, Casadei
Gardini A, Neri LM, Frassineti GL, Amadori D, Ulivi P. Circulating VEGF and eNOS
variations as predictors of outcome in metastatic colorectal cancer patients
receiving bevacizumab. Sci Rep. 2017 May 2;7(1):1293. doi:
10.1038/s41598-017-01420-0. PMID: 28465540; PMCID: PMC5431064.
94: Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M,
Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O.
Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget. 2017 May
16;8(20):33897-33910. doi: 10.18632/oncotarget.15406. PMID: 28420805; PMCID:
PMC5464921.
95: Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M,
Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M,
Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M,
Calvetti L, Cardarelli N, Aprile G. Immunotherapy for colorectal cancer: where
are we heading? Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi:
10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Erratum in: Expert Opin Biol
Ther. 2017 Jun;17 (6):791. PMID: 28375039.
96: Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V,
Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG,
Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S.
Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev
Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub
2017 Feb 4. PMID: 28259290.
97: Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi
L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani
G, Tassinari D, Cascinu S, Frassineti GL. Metronomic capecitabine versus best
supportive care as second-line treatment in hepatocellular carcinoma: a
retrospective study. Sci Rep. 2017 Feb 13;7:42499. doi: 10.1038/srep42499. PMID:
28211921; PMCID: PMC5304169.
98: Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini
A, Marisi G, Baron Toaldo M, Baglioni M, Salvatore V, Callegari E, Baldassarre
M, Galassi M, Giovannini C, Cescon M, Ravaioli M, Negrini M, Bolondi L,
Gramantieri L. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib
Resistance through Inhibition of Caspase-3-Mediated Apoptosis. Clin Cancer Res.
2017 Jul 15;23(14):3953-3965. doi: 10.1158/1078-0432.CCR-16-1464. Epub 2017 Jan
17. PMID: 28096271.
99: Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codecà C, Broglia
CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A,
Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D,
Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O;
Early Palliative Care Italian Study Group (EPCISG). Erratum to "Systematic
versus on-demand early palliative care: A randomised clinical trial assessing
quality of care and treatment aggressiveness near the end of life" [Eur J Cancer
69 (2016) 110-118]. Eur J Cancer. 2017 Feb;72:272-273. doi:
10.1016/j.ejca.2016.11.024. Epub 2016 Dec 24. Erratum for: Eur J Cancer. 2016
Dec;69:110-118. PMID: 28027830.
100: Capelli L, Casadei Gardini A, Scarpi E, Frassineti GL, Saragoni L, Puccetti
M, Scartozzi M, Giannini M, Tamberi S, Corbelli J, Ulivi P. No evidence of NRAS
mutation in squamous cell anal carcinoma (SCAC). Sci Rep. 2016 Nov 25;6:37621.
doi: 10.1038/srep37621. PMID: 27886225; PMCID: PMC5122846.
101: Maltoni M, Scarpi E, Dall'Agata M, Schiavon S, Biasini C, Codecà C, Broglia
CM, Sansoni E, Bortolussi R, Garetto F, Fioretto L, Cattaneo MT, Giacobino A,
Luzzani M, Luchena G, Alquati S, Quadrini S, Zagonel V, Cavanna L, Ferrari D,
Pedrazzoli P, Frassineti GL, Galiano A, Casadei Gardini A, Monti M, Nanni O;
Early Palliative Care Italian Study Group (EPCISG). Systematic versus on-demand
early palliative care: A randomised clinical trial assessing quality of care and
treatment aggressiveness near the end of life. Eur J Cancer. 2016
Dec;69:110-118. doi: 10.1016/j.ejca.2016.10.004. Epub 2016 Nov 4. Erratum in:
Eur J Cancer. 2017 Feb;72 :272-273. PMID: 27821313.
102: Casadei Gardini A, Tenti E, Masini C, Nanni O, Scarpi E, Valgiusti M,
Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori
D, Minguzzi M, Frassineti GL. Multicentric survey on dose reduction/interruption
of cancer drug therapy in 12.472 patients: indicators of suspected adverse
reactions. Oncotarget. 2016 Jun 28;7(26):40719-40724. doi:
10.18632/oncotarget.8942. PMID: 27119511; PMCID: PMC5130038.
103: Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini
D, de Stefano G, Marisi G, Negri FV, Foschi FG, Valgiusti M, Ercolani G,
Frassineti GL. Immune inflammation indicators and implication for immune
modulation strategies in advanced hepatocellular carcinoma patients receiving
sorafenib. Oncotarget. 2016 Oct 11;7(41):67142-67149. doi:
10.18632/oncotarget.11565. PMID: 27613839; PMCID: PMC5341863.
104: Maltoni M, Scarpi E, Dall'Agata M, Zagonel V, Bertè R, Ferrari D, Broglia
CM, Bortolussi R, Trentin L, Valgiusti M, Pini S, Farolfi A, Casadei Gardini A,
Nanni O, Amadori D; Early Palliative Care Italian Study Group (EPCISG).
Systematic versus on-demand early palliative care: results from a multicentre,
randomised clinical trial. Eur J Cancer. 2016 Sep;65:61-8. doi:
10.1016/j.ejca.2016.06.007. Epub 2016 Jul 26. PMID: 27472648.
105: Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi
M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P. Efficacy
of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response
in synchronous BRAF wild type-hepatocellular carcinoma: a case report. BMC
Cancer. 2016 Jul 7;16:429. doi: 10.1186/s12885-016-2463-2. PMID: 27388325;
PMCID: PMC4937544.
106: Faloppi L, Bianconi M, Memeo R, Casadei Gardini A, Giampieri R, Bittoni A,
Andrikou K, Del Prete M, Cascinu S, Scartozzi M. Lactate Dehydrogenase in
Hepatocellular Carcinoma: Something Old, Something New. Biomed Res Int.
2016;2016:7196280. doi: 10.1155/2016/7196280. Epub 2016 May 29. PMID: 27314036;
PMCID: PMC4903134.
107: Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N,
Bianconi M, Giampieri R, Valgiusti M, Brunetti O, Bittoni A, Andrikou K, Lai E,
Dessì A, Cascinu S, Scartozzi M. The correlation between LDH serum levels and
clinical outcome in advanced biliary tract cancer patients treated with first
line chemotherapy. Sci Rep. 2016 Apr 11;6:24136. doi: 10.1038/srep24136. PMID:
27063994; PMCID: PMC4827080.
108: Casadei Gardini A, Marisi G, Faloppi L, Scarpi E, Foschi FG, Iavarone M,
Lauletta G, Corbelli J, Valgiusti M, Facchetti F, Della Corte C, Neri LM,
Tamberi S, Cascinu S, Scartozzi M, Amadori D, Nanni O, Tenti E, Ulivi P,
Frassineti GL. eNOS polymorphisms and clinical outcome in advanced HCC patients
receiving sorafenib: final results of the ePHAS study. Oncotarget. 2016 May
10;7(19):27988-99. doi: 10.18632/oncotarget.8569. PMID: 27058899; PMCID:
PMC5053704.
109: Casadei Gardini A, Scarpi E, Marisi G, Foschi FG, Donati G, Giampalma E,
Faloppi L, Scartozzi M, Silvestris N, Bisulli M, Corbelli J, Gardini A, La Barba
G, Veneroni L, Tamberi S, Cascinu S, Frassineti GL. Early onset of hypertension
and serum electrolyte changes as potential predictive factors of activity in
advanced HCC patients treated with sorafenib: results from a retrospective
analysis of the HCC-AVR group. Oncotarget. 2016 Mar 22;7(12):15243-51. doi:
10.18632/oncotarget.7444. PMID: 26893366; PMCID: PMC4924783.
110: Casadei Gardini A, Mariotti M, Lucchesi A, Pini S, Valgiusti M, Bravaccini
S, Del Monte A, Burgio MA, Marisi G, Amadori D, Frassineti GL. Paraneoplastic
lipase and amylase production in a patient with small-cell lung cancer: case
report. BMC Cancer. 2016 Feb 17;16:118. doi: 10.1186/s12885-016-2167-7. PMID:
26887807; PMCID: PMC4758001.
111: Casadei Gardini A, Carloni S, Scarpi E, Maltoni P, Dorizzi RM, Passardi A,
Frassineti GL, Cortesi P, Giannini MB, Marisi G, Amadori D, Lucchesi A.
Prognostic role of serum concentrations of high-sensitivity C-reactive protein
in patients with metastatic colorectal cancer: results from the ITACa trial.
Oncotarget. 2016 Mar 1;7(9):10193-202. doi: 10.18632/oncotarget.7166. PMID:
26848624; PMCID: PMC4891113.
112: Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris
N, Masi G, Vivaldi C, Brunetti O, Tamberi S, Foschi FG, Tamburini E, Tenti E,
Ricca Rosellini S, Ulivi P, Cascinu S, Nanni O, Frassineti GL. Effects of
metformin on clinical outcome in diabetic patients with advanced HCC receiving
sorafenib. Expert Opin Pharmacother. 2015;16(18):2719-25. doi:
10.1517/14656566.2015.1102887. Epub 2015 Oct 29. PMID: 26513009.
113: Lucchesi A, Fattori PP, Ronconi S, Carloni S, Casadei Gardini A, Musuraca
G, Napolitano M. Atypical presentations of thrombotic thrombocytopenic purpura
in middle-aged women with recurrent cerebral macrovascular thrombosis: a case
report. Ann Hematol. 2015 Sep;94(9):1597-8. doi: 10.1007/s00277-015-2415-y. Epub
2015 Jun 9. PMID: 26051903.
114: Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti
G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D, Calistri D.
Improved stool DNA integrity method for early colorectal cancer diagnosis.
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2553-60. doi:
10.1158/1055-9965.EPI-14-0379. Epub 2014 Aug 15. PMID: 25128402.
115: Rengucci C, De Maio G, Casadei Gardini A, Zucca M, Scarpi E, Zingaretti C,
Foschi G, Tumedei MM, Molinari C, Saragoni L, Puccetti M, Amadori D, Zoli W,
Calistri D. Promoter methylation of tumor suppressor genes in pre-neoplastic
lesions; potential marker of disease recurrence. J Exp Clin Cancer Res. 2014 Aug
5;33(1):65. doi: 10.1186/s13046-014-0065-x. PMID: 25091577; PMCID: PMC4274757.
116: Cecconetto L, Casadei Gardini A, Tenti E, Maltoni R, Bravaccini S, Oboldi
D, Zoli W, Serra P, Donati C, Sarti S, Amadori D, Rocca A. Long-term complete
response in a patient with liver metastases from breast cancer treated with
metronomic chemotherapy. Tumori. 2014 May-Jun;100(3):e79-82. doi:
10.1700/1578.17238. PMID: 25076256.
117: Casadei Gardini A, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S,
Scarpi E, Passardi A, Zoli W, Ragazzini A, Amadori D, Frassineti GL. KRAS, BRAF
and PIK3CA status in squamous cell anal carcinoma (SCAC). PLoS One. 2014 Mar
18;9(3):e92071. doi: 10.1371/journal.pone.0092071. PMID: 24642661; PMCID:
PMC3958420.
118: Terragni R, Casadei Gardini A, Sabattini S, Bettini G, Amadori D, Talamonti
C, Vignoli M, Capelli L, Saunders JH, Ricci M, Ulivi P. EGFR, HER-2 and KRAS in
canine gastric epithelial tumors: a potential human model? PLoS One. 2014 Jan
15;9(1):e85388. doi: 10.1371/journal.pone.0085388. Erratum in: PLoS One.
2015;10(3):e0119048. PMID: 24454858; PMCID: PMC3893207.
119: Monti M, Foca F, Casadei Gardini A, Valgiusti M, Frassineti GL, Amadori D.
Retrospective analysis on the management of metastatic gastric cancer patients.
A mono-institutional experience. What happens in clinical practice? Tumori. 2013
Sep-Oct;99(5):583-8. doi: 10.1700/1377.15306. PMID: 24362861.
120: Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E,
Burgio MA, Amadori D, Frassineti GL. Separate episodes of capillary leak
syndrome and pulmonary hypertension after adjuvant gemcitabine and three years
later after nab-paclitaxel for metastatic disease. BMC Cancer. 2013 Nov
12;13:542. doi: 10.1186/1471-2407-13-542. PMID: 24215543; PMCID: PMC3840643.
121: Burgio SL, Menna C, Papiani G, Casadei Gardini A, De Luigi N, Corsi R,
Rosti G. Alpha-fetoprotein surge following high-dose chemotherapy in germ cell
tumours. J Chemother. 2013 Apr;25(2):119-22. doi:
10.1179/1973947812Y.0000000044. PMID: 23684360.
122: Lucchesi A, Carloni S, Cangini D, Frassineti GL, Casadei Gardini A. Acute
oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report and
results from a cytoflourimetric assay of platelet fibrinogen receptor. J Clin
Oncol. 2013 Jun 1;31(16):2061-2. doi: 10.1200/JCO.2012.48.3248. Epub 2013 Apr
22. PMID: 23610122.
123: Casadei Gardini A, Pieri F, Fusaroli P, Oboldi D, Passardi A, Monti M,
Rosetti P, Calpona S, Valgiusti M, Ragazzini A, Amadori D, Frassineti GL.
Hemangioblastoma of the gastrointestinal tract: a first case. Int J Surg Pathol.
2013 Apr;21(2):192-6. doi: 10.1177/1066896912475082. PMID: 23516170.
124: Clavarezza M, Mustacchi G, Casadei Gardini A, Del Mastro L, De Matteis A,
Riccardi F, Adamo V, Aitini E, Amoroso D, Marchetti P, Gori S, Carrozza F,
Maiello E, Giotta F, Dondi D, Venturini M. Biological characterization and
selection criteria of adjuvant chemotherapy for early breast cancer: experience
from the Italian observational NEMESI study. BMC Cancer. 2012 Jun 6;12:216. doi:
10.1186/1471-2407-12-216. PMID: 22672524; PMCID: PMC3433340.
125: Ulivi P, Capelli L, Valgiusti M, Zoli W, Scarpi E, Chiadini E, Rosetti P,
Bravaccini S, Calistri D, Saragoni L, Casadei Gardini A, Ragazzini A, Frassineti
GL, Amadori D, Passardi A. Predictive role of multiple gene alterations in
response to cetuximab in metastatic colorectal cancer: a single center study. J
Transl Med. 2012 May 8;10:87. doi: 10.1186/1479-5876-10-87. PMID: 22569004;
PMCID: PMC3404915.
126: Calistri D, Rengucci C, Casadei Gardini A, Frassineti GL, Scarpi E, Zoli W,
Falcini F, Silvestrini R, Amadori D. Fecal DNA for noninvasive diagnosis of
colorectal cancer in immunochemical fecal occult blood test-positive
individuals. Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2647-54. doi:
10.1158/1055-9965.EPI-10-0291. PMID: 20929882.
Il titolare del presente curriculum vitae, pubblicato online sul portale www.unisr.it, è garante in via esclusiva della correttezza e della veridicità dei dati e delle informazioni in esso riportate e del loro eventuale e puntuale aggiornamento. Egli è dunque il diretto ed unico responsabile dei contenuti indicati nei propri curricula.